FDA Inspection 1066677 — Liveyon

Liveyon — FEI 3013957857

The FDA completed an inspection of Liveyon on September 21, 2018 in Yorba Linda, CA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 8 citations were issued during this inspection. Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
September 21, 2018
Fiscal Year
2018
Product Type
Biologics
Project Area
Human Cellular, Tissue, and Gene Therapies
Location
Yorba Linda, CA (United States)

Citations

IDCFRDescription
1223921 CFR 1271.55(b)(2)Listing and interpretation of CD tests performed
1237321 CFR 1271.200(d)Inspected routinely
1241621 CFR 1271.260(e)Storage temperatures recorded, maintained
1242421 CFR 1271.265(c)(1)Release criteria verified, documented
1242921 CFR 1271.265(d)Shipping conditions appropriate
1246921 CFR 1271.350(a)(1)Adverse reaction reporting to FDA
188321 CFR 211.165(a)Testing and release for distribution
261921 CFR 211.198(b)(2)Complaint Investigation/Follow-Up Findings